Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 2, 2026 · Investor press release · Financial statements
GYRE THERAPEUTICS, INC.
49
Investor press release
Jun 2, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Investor press release · Financial statements |
| Primary topic | Investor press release |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | GYRE THERAPEUTICS, INC. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 A Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory Diseases and Cancer This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regar… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 1, 2026 |
| Accession number | 0001140361-26-023625 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Financial statements and exhibits See Analysis tab for workforce implications |
